SEATTLE--(BUSINESS WIRE)--Light Sciences Oncology today announced the treatment of the first patient in its Phase II trial for glioma. The open label study is being conducted in Europe and is expected to enroll 12 patients. Its primary objective is to demonstrate the safety of Light Infusion Therapy™ (Litx™) with increasing light doses in the treatment of primary or recurrent glioma — including glioblastoma and astrocytoma.
